Today before the opening bell, International Stem Cell Corp., a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products, announced that Professor Evan Snyder and Dr. Rosasio Sánchez-Pernaute are now scientific advisors on the company’s Parkinson’s disease program.
Evan Snyder, MD, PhD is a Professor at the Sanford-Burnham Medical Research Institute and director of Sanford-Burnham’s stem cell program and research center. Regarded as one of the pioneers of stem cell research, particularly with regard to regenerative medicine applications, Prof. Snyder is an expert on Parkinson’s disease (PD). In fact, he was one of the first scientists to identify neural stem cells and to document the ability of stem cells to migrate to injured or diseased regions of the brain. Prof. Snyder is a recipient of an Early Translational Award from the California Institute for Regenerative Medicine (CIRM) to research into cell based therapies for PD.
Rosario Sánchez-Pernaute, MD, PhD is an internationally recognized expert on the use of stem cells to treat Parkinson’s disease. While Assistant Professor in Neurology at Harvard Medical School Dr. Sánchez-Pernaute was one of the first scientists to demonstrate the possibility of using parthenogenetic stem cells to treat the causes of PD in a non-human primate model.
“We are extremely fortunate to work with two of the world’s leading experts in Parkinson’s disease and stem cell research,” say Dr. Ruslan Semechkin, Vice President of Research and Development, “Prof. Snyder and Dr. Sánchez-Pernaute will add invaluable expertise to our Parkinson’s disease program and provide input into our first non-human primate pre-clinical study which uses the most reliable and predictive model of Parkinson’s in humans.”
For additional information on ISCO, visit the company’s website at www.internationalstemcell.com
Let us hear your thoughts: International Stem Cell Corp. Message Board